Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wasabi Sulfinyl is a dietary supplement and functional food ingredient developed by Kinjirushi Co., Ltd., derived from the rhizomes and roots of Japanese wasabi (*Eutrema japonicum*). Its primary active component is 6-methylsulfinylhexyl isothiocyanate (6-MSITC), also known as hexaraphane. Wasabi Sulfinyl is marketed and studied for its potential to improve cognitive functions, such as memory, attention, and judgment, particularly in middle-aged and older adults. It is also investigated for its neuroprotective, antioxidant, and anti-inflammatory properties, with research interest extending to chronic fatigue syndrome (ME/CFS), brain fog, metabolic syndrome, and neurodegenerative diseases like Alzheimer's and Parkinson's disease. Mechanistically, it acts on multiple pathways, including Nrf2/Keap1-ARE activation, GSK-3β inhibition, and modulation of PPAR, AMPK, PI3K/Akt/mTOR, and MAPK signaling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wasabi sulfinyl.